Healthpeak Properties Adds New Director

Ticker: DOC · Form: 8-K · Filed: Apr 7, 2025 · CIK: 765880

Healthpeak Properties, INC. 8-K Filing Summary
FieldDetail
CompanyHealthpeak Properties, INC. (DOC)
Form Type8-K
Filed DateApr 7, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: board-appointment, director-departure, governance

Related Tickers: PEAK

TL;DR

Healthpeak Properties adds Eastman Chemical vet Thomas Hargrave to its board.

AI Summary

Healthpeak Properties, Inc. announced on April 7, 2025, that its Board of Directors elected Thomas J. Hargrave, Jr. as a new director, effective April 2, 2025. Hargrave, who previously served as Chairman and CEO of Eastman Chemical Company, will serve on the Nominating and Corporate Governance Committee and the Compensation Committee. This appointment follows the departure of director John E. Williams.

Why It Matters

The addition of an experienced director like Thomas J. Hargrave, Jr. can bring fresh perspectives and expertise to the board, potentially influencing strategic decisions and corporate governance.

Risk Assessment

Risk Level: low — The filing reports a routine board appointment and director departure, which typically carries low risk.

Key Players & Entities

FAQ

Who is the new director appointed to Healthpeak Properties' board?

Thomas J. Hargrave, Jr. was elected as a new director.

When was the new director appointment effective?

The appointment was effective April 2, 2025.

Which committees will Thomas J. Hargrave, Jr. serve on?

He will serve on the Nominating and Corporate Governance Committee and the Compensation Committee.

Who is the departing director?

John E. Williams is the departing director.

What was Thomas J. Hargrave, Jr.'s previous role?

He previously served as Chairman and CEO of Eastman Chemical Company.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 by Thomas J. Hargrave, Jr. regarding HEALTHPEAK PROPERTIES, INC. (DOC).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing